CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

budesonide

Last Updated: November 20, 2020
Result type: Reports
Project Number: SR0666-000
Product Line: Reimbursement Review

Generic Name: budesonide

Brand Name: Jorveza

Manufacturer: AVIR Pharma Inc

Therapeutic Area: Maintenance of Eosinophilic esophagitis in adults

Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

Manufacturer Requested Reimbursement Criteria1: For the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE), as per Health Canada indication.

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 07, 2020
Call for patient/clinician input closedNovember 26, 2020
Submission receivedNovember 05, 2020
Submission acceptedNovember 19, 2020
Review initiatedNovember 20, 2020
Draft CADTH review report(s) provided to sponsor for commentFebruary 10, 2021
Deadline for sponsors commentsFebruary 22, 2021
CADTH responses on draft review report(s) provided to sponsorApril 09, 2021
Expert committee meeting (initial)April 21, 2021
Draft recommendation issued to sponsorMay 03, 2021
To
May 05, 2021
Submit Feedback